Skip to main content
SpringerLink
Log in

Rosiglitazone

Trials, Tribulations and Termination

  • Editorial
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1999; 354 (9178): 602]. Lancet 1998; 352(9131): 837–53

    Article  Google Scholar 

  2. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1998; 352 (9139): 1558]. Lancet 1998; 352(9131): 854–65

    Article  Google Scholar 

  3. DeFronzo RA, Ferrannini E. Insulin resistance: a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14(3): 173–94

    Article  CAS  PubMed  Google Scholar 

  4. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11): 1106–18

    Article  PubMed  Google Scholar 

  5. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65(3): 385–411

    Article  CAS  PubMed  Google Scholar 

  6. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334(9): 574–9

    Article  CAS  PubMed  Google Scholar 

  7. Stout RW. Hyperinsulinemia and atherosclerosis. Diabetes 1996; 45 Suppl. 3: S45–6

    Article  CAS  PubMed  Google Scholar 

  8. Hemmingsen B, Lund SS, Wetterslev J, et al. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol 2009 Jul; 161(1): 1–9

    Article  CAS  PubMed  Google Scholar 

  9. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes: new agents reduce insulin resistance but need long term clinical trials. BMJ 2000; 321(7256): 252–3

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Nattrass M, Alberti KG. Biguanides. Diabetologia 1978; 14(2): 71–4

    Article  CAS  PubMed  Google Scholar 

  11. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11(4): 223–41

    Article  CAS  PubMed  Google Scholar 

  12. Krentz AJ. Sulfonylureas in the prevention of vascular complications: from UKPDS to the ADVANCE study, in the metabolic syndrome: diabetes, obesity, hyperlipidemia and hypertension. In: Crepaldi GT, Avogaro AA, editors. Amsterdam: Excerpta Medica International Conference Series, 2002: 261–77

  13. Johnsen SP, Monster TB, Olsen ML, et al. Risk and shortterm prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 2006; 13(2): 134–40

    Article  CAS  PubMed  Google Scholar 

  14. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28(7): 1547–54

    Article  CAS  PubMed  Google Scholar 

  15. Gale EA. Diabetes in the UK: time for a reality check? Diabet Med 2010; 27(9): 973–6

    Article  CAS  PubMed  Google Scholar 

  16. Dormandy JA, Charbonnel B, Eckland DJ, et al., PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279–89

    Article  CAS  PubMed  Google Scholar 

  17. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368(9541): 1096–105

    Article  CAS  PubMed  Google Scholar 

  18. Kahn SE, Haffner SM, Heise MA, et al., ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355(23): 2427–43

    Article  CAS  PubMed  Google Scholar 

  19. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298(10): 1180–8

    Article  CAS  PubMed  Google Scholar 

  20. Nissen SE, Nicholls SJ, Wolski K, et al., PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299(13): 1561–73

    Article  CAS  PubMed  Google Scholar 

  21. Krentz A. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications. Diabetes Metab Res Rev 2009; 25(2): 112–26

    Article  CAS  PubMed  Google Scholar 

  22. Nathan DM, Buse JB, Davidson MB, et al., American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52(1): 17–30

    Article  CAS  PubMed  Google Scholar 

  23. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control [published erratum appears in Endocr Pract 2009; 15 (7): 768–70]. Endocr Pract 2009; 15(6): 540–59

    Article  PubMed  Google Scholar 

  24. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents (partial update of CG66) [online]. Available from URL: http://www.nice.org.uk/CG87 [Accessed 2010 Nov 22]

  25. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147(8): 578–81

    Article  PubMed  Google Scholar 

  26. Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinediones: what do meta-analyses really tell us? Diabetes Obes Metab 2010; 12: 1023–35

    Article  CAS  PubMed  Google Scholar 

  27. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 2007; 357(1): 28–38

    Article  CAS  PubMed  Google Scholar 

  28. Home PD, Pocock SJ, Beck-Nielsen H, et al., RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373(9681): 2125–35

    Article  CAS  PubMed  Google Scholar 

  29. BARI 2D Study Group, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360(24): 2503–15

    Article  CAS  PubMed  Google Scholar 

  30. US FDA. Avandia (rosiglitazone): REMS — risk of cardiovascular events [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226994.htm [Accessed 2010 Dec 6]

  31. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim [online]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=true [Accessed 2010 Dec 6]

  32. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304(4): 411–8

    Article  CAS  PubMed  Google Scholar 

  33. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. Epub 2010 Jun 28

  34. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 2010; 363(16): 1489–91

    Article  Google Scholar 

  35. Blind E, Dunder K, de Graeff PA, et al. Rosiglitazone: a European regulatory perspective. Diabetologia. Epub 2010 Dec 14

  36. Shah ND, Montori VM, Krumholz HM, et al. Responding to an FDA warning: geographic variation in the use of rosiglitazone. N Engl J Med 2010; 363: 2081–4

    Article  CAS  PubMed  Google Scholar 

  37. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294(20): 2581–6

    Article  CAS  PubMed  Google Scholar 

  38. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008 Dec [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulator [Accessed 2010 Nov 12]

  39. EMA (2008). Concept paper on the need for revision of the note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003182.pdf [Accessed 2010 Dec 16]

  40. Cohen D. Rosiglitazone: what went wrong? BMJ 2010 Sep 6; 341: c4848

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Dr Krentz thanks Professor Alan Sinclair for his constructive comments on the manuscript.

Dr Krentz has received professional consultancy fees from GlaxoSmithKline and Takeda and has served as a paid member of the speakers’ bureaus of both companies. He has also received grant funding and fees for consultancies and lectures from other diabetes drug manufacturers including Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly, NovoNordisk, Pfizer, Roche and Servier.

Author information

Authors and Affiliations

  1. Institute for Diabetes in Older People, Bedfordshire and Hertfordshire Postgraduate Medical School, University of Bedfordshire, Putteridge Bury Campus, Hitchin Road, Luton, LU2 8LE, UK

    Andrew J. Krentz

Authors
  1. Andrew J. Krentz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew J. Krentz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krentz, A.J. Rosiglitazone. Drugs 71, 123–130 (2011). https://doi.org/10.2165/11585300-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11585300-000000000-00000

Search

Navigation